Indications for use:
Proposed for use in the complex therapy of AIDS.
An antiviral product that inhibits the replication of retroviruses (suppressing the formation of nucleic acids during the reproduction of viruses), including human immunodeficiency virus (AIDS).
Zidovudine (Zidovudine) method of administration and dose:
Doses are set individually and depend on the stage of the disease, the degree of preservation of bone marrow reserves, the body weight of the patient, and the response to treatment. The initial daily dose for patients weighing less than 70 kg is 1.2 g. The daily dose is divided into 6 doses. The maximum daily dose is 1.5 g. The maintenance dose is 1.0 g per day in 4-5 doses. Adjustment of the maintenance dose is carried out in accordance with the reaction of the peripheral blood. Treatment should be discontinued if the hemoglobin level is below 7.5 r/dl and/or the neutrophil count is less than 0.75 x 109/l. After the restoration of these indicators (usually after a 2-week break), treatment can be resumed. Children are prescribed at the rate of 0.15-0.18 g / m2 of body surface area per day, distributing the daily dose into 4 doses.
Zidovudine (zidovudine) contraindications:
Contraindicated in pregnancy and lactation.
You can not prescribe zidovudine simultaneously with other products that cause leukopenia and other disorders of the blood picture.
Zidovudine (Zidovudine) side effects:
When using the product, severe leukopenia (decrease in the level of leukocytes in the blood) and / or granulocytopenia (decrease in the level of granulocytes in the blood), anemia (decrease in hemoglobin in the blood) and other side effects may develop. It is necessary to individually select the dose of the product and carefully monitor the condition of the patient.